| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2005 | EP0977755B1 Heterocyclic compounds and their preparation and use |
| 07/13/2005 | EP0949249B1 Process for producing imidazole derivatives |
| 07/13/2005 | EP0938308B1 Antiparasitic agents |
| 07/13/2005 | EP0750512B1 A medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction |
| 07/13/2005 | CN1639575A In vitro model for priocidal activity |
| 07/13/2005 | CN1639358A Multiple virus replicon culture systems |
| 07/13/2005 | CN1639324A Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| 07/13/2005 | CN1639318A Antimicrobial composition |
| 07/13/2005 | CN1639312A Immidazoline quats |
| 07/13/2005 | CN1639199A Novel branched sialo-sugar molecules and antiviral agents using the same |
| 07/13/2005 | CN1639191A 鼠李糖结合蛋白 Rhamnose-binding protein |
| 07/13/2005 | CN1639187A Macrocyclic peptides active against the hepatitis C virus |
| 07/13/2005 | CN1639180A Aryl 5-thio-beta-D-glucopyranoside derivatives and remedies for diabetes containing the same |
| 07/13/2005 | CN1639178A Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases |
| 07/13/2005 | CN1639168A Bicyclic pyridine and pyrimidine P38 kinase inhibitors |
| 07/13/2005 | CN1639167A Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity |
| 07/13/2005 | CN1639165A Purine derivatives as kinase inhibitors |
| 07/13/2005 | CN1639163A Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6, 7, 8, 9-tetrahydro-4h-pyrido-(1, 2-a) pyrimidin-4-one |
| 07/13/2005 | CN1639162A Pyrido(2, 1-a)isoquinoline derivatives as DPP-IV inhibitors |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639160A Process for preparing crystalline form I of cabergoline |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639158A Thiazole derivatives as NPY receptor antagonists |
| 07/13/2005 | CN1639157A 2-acylaminothiazole derivative or salt thereof |
| 07/13/2005 | CN1639156A 8'4-'3-(5-fluoro-1H-indol-3-yl)propyl!-1-piperazinyl!-2-methyl-2H-1, 4-benzoxazin -3(4H)-one methanesulfonate with high affinity for the dopamine D2 receptor and the seotonin reuptake site |
| 07/13/2005 | CN1639155A Pyrrolidine oxadiazole- and thiadiazole derivatives |
| 07/13/2005 | CN1639154A Pyranones useful as ATM inhibitors |
| 07/13/2005 | CN1639153A Indolylmaleimide derivatives |
| 07/13/2005 | CN1639152A Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors |
| 07/13/2005 | CN1639151A Novel azepane derivatives |
| 07/13/2005 | CN1639150A 异喹啉衍生物 Isoquinoline derivatives |
| 07/13/2005 | CN1639149A Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 07/13/2005 | CN1639148A 喹啉衍生物 Quinoline derivatives |
| 07/13/2005 | CN1639146A Fused tricyclic heterocycles useful for treating hyper-proliferative disorders |
| 07/13/2005 | CN1639145A Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders |
| 07/13/2005 | CN1639142A Method for producing 3-amidinophenylalanine derivatives |
| 07/13/2005 | CN1639141A New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors |
| 07/13/2005 | CN1639140A Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 07/13/2005 | CN1639139A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors |
| 07/13/2005 | CN1639138A Biphenylmethyl-thiazolidinediones and analogues and their use as PPAR-gamma activators |
| 07/13/2005 | CN1639137A Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxadiazol-2-ones, the production thereof and their use in medicaments |
| 07/13/2005 | CN1639136A Oxazolidinone and/or isoxazoline as antibacterial agents |
| 07/13/2005 | CN1639135A N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials |
| 07/13/2005 | CN1639133A Novel antibacterial compounds, process for their preparation and pharmaceutical compositions containing them |
| 07/13/2005 | CN1639132A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/13/2005 | CN1639130A Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 07/13/2005 | CN1639126A Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639124A Aminotetralin derivatives as muscarinic receptor antagonists |
| 07/13/2005 | CN1639123A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 07/13/2005 | CN1639122A Azaspiro compounds for the treatment of pain |
| 07/13/2005 | CN1639121A 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 07/13/2005 | CN1639120A Indolamid derivatives which possess glycogenphosphorylase inhibitory activity |
| 07/13/2005 | CN1639119A Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 07/13/2005 | CN1639115A Semicarbazide derivatives and their use as antithrombotics |
| 07/13/2005 | CN1639112A Substituted amides active at the cannabinoid-1 receptor |
| 07/13/2005 | CN1639110A Haloacetamide and azide substituted compounds and methods of use thereof |
| 07/13/2005 | CN1638823A N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 07/13/2005 | CN1638805A Pharmaceutical formulation of IRESSA comprising a water-soluble cellulose derivative |
| 07/13/2005 | CN1638804A Liquid matrix undergoing phase transfer in vivo and liquid oral preparations |
| 07/13/2005 | CN1638803A Tablets quickly disintegrating in oral cavity |
| 07/13/2005 | CN1638802A Percutaneous absorption promoters and compositions for treating athlete's foot |
| 07/13/2005 | CN1638801A Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof |
| 07/13/2005 | CN1638799A Human mast cell-expressed membrane proteins |
| 07/13/2005 | CN1638797A Cancer treatment |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638780A Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
| 07/13/2005 | CN1638779A Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
| 07/13/2005 | CN1638778A Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| 07/13/2005 | CN1638777A Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 07/13/2005 | CN1638776A Substituted 3-aryl-5-aryl-[1, 2, 4]-oxadiazoles and analogs |
| 07/13/2005 | CN1638775A Nitric oxide donors for treatment of disease and injury |
| 07/13/2005 | CN1638774A Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops |
| 07/13/2005 | CN1638773A Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient |
| 07/13/2005 | CN1638772A Anti-viral compounds |
| 07/13/2005 | CN1638771A Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered oral |
| 07/13/2005 | CN1638770A Composition and potentiating method |
| 07/13/2005 | CN1638769A Ophthalmic composition comprising ascomycin |
| 07/13/2005 | CN1638768A Thiazole and oxazole derivatives that modulate PPAR activity |
| 07/13/2005 | CN1638767A Combinations comprising epothilone derivatives and alkylating agent |
| 07/13/2005 | CN1638766A Use of substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase |
| 07/13/2005 | CN1638765A Mediators of Hedgehog signaling pathways, compositions and uses related thereto |
| 07/13/2005 | CN1638764A Eye drops containing tetrazole derivative |
| 07/13/2005 | CN1638762A Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| 07/13/2005 | CN1638761A Azetidine derivatives as CCR-3 receptor antagonists |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638759A Pharmaceutical composition comprising a bisphosphonate and a COX-2 inhibitor for the treatment of bone diseases |
| 07/13/2005 | CN1638758A Stimulation of CPT-1 as a means to reduce weight |
| 07/13/2005 | CN1638757A 组织蛋白酶半胱氨酸蛋白酶抑制剂 Cathepsin cystatin |
| 07/13/2005 | CN1638756A R-bambuterol, its preparation and therapeutic uses |
| 07/13/2005 | CN1638755A Body temperature elevating agents |
| 07/13/2005 | CN1638754A Combined use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638752A Pharmaceutical compositions |
| 07/13/2005 | CN1638751A Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers CRP and SAA |
| 07/13/2005 | CN1638750A Pharmaceutical compositions for oral use, containing, in combination, metformin and glyclazide |
| 07/13/2005 | CN1638749A Ambroxol for treating painful conditions in the mouth and pharyngeal cavity |
| 07/13/2005 | CN1638747A Sustained release pharmaceutical composition |
| 07/13/2005 | CN1638746A Colonic release composition |
| 07/13/2005 | CN1638745A Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |